Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 3
1998 4
1999 8
2000 28
2001 157
2002 354
2003 622
2004 685
2005 774
2006 868
2007 1055
2008 994
2009 1095
2010 1114
2011 1215
2012 1163
2013 1104
2014 1116
2015 979
2016 957
2017 885
2018 845
2019 824
2020 863
2021 859
2022 809
2023 737
2024 393

Text availability

Article attribute

Article type

Publication date

Search Results

18,281 results

Results by year

Filters applied: . Clear all
Page 1
Kinase drug discovery 20 years after imatinib: progress and future directions.
Cohen P, Cross D, Jänne PA. Cohen P, et al. Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17. Nat Rev Drug Discov. 2021. PMID: 34002056 Free PMC article. Review.
Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of protein and lipid kinases, resulting in the approval of more than 70 new drugs since imatinib was approved in 2001. These compounds …
Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of …
The argument for using imatinib in CML.
Claudiani S, Apperley JF. Claudiani S, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504305 Free PMC article. Review.
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for patients with this disease is one of the major success stories of modern cancer medicine. .. …
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid le …
Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination.
Sun X, Zhang Q, Lin X, Shu P, Gao X, Shen K. Sun X, et al. Cell Death Dis. 2023 Dec 18;14(12):839. doi: 10.1038/s41419-023-06300-2. Cell Death Dis. 2023. PMID: 38110356 Free PMC article.
Imatinib (IM) has significantly improved the prognosis of gastrointestinal stromal tumor (GIST) patients, but some patients still have primary resistance to IM, and approximately half of patients develop acquired drug resistance within 2 years of treatment, necessitating e …
Imatinib (IM) has significantly improved the prognosis of gastrointestinal stromal tumor (GIST) patients, but some patients still hav …
Belumosudil Mesylate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Nov 9;78(22):2002-2004. doi: 10.1093/ajhp/zxab335. Am J Health Syst Pharm. 2021. PMID: 34498057 No abstract available.
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Galkin A, Sitapara R, Clemons B, Garcia E, Kennedy M, Guimond D, Carter LL, Douthitt A, Osterhout R, Gandjeva A, Slee D, Salter-Cid L, Tuder RM, Zisman LS. Galkin A, et al. Eur Respir J. 2022 Dec 1;60(6):2102356. doi: 10.1183/13993003.02356-2021. Print 2022 Dec. Eur Respir J. 2022. PMID: 35680144 Free PMC article.
We examined the preclinical efficacy of inhaled seralutinib, a unique small-molecule PDGFR/CSF1R/c-KIT kinase inhibitor in clinical development for PAH, in comparison to a proof-of-concept kinase inhibitor, imatinib. METHODS: Seralutinib and imatinib potency and sel …
We examined the preclinical efficacy of inhaled seralutinib, a unique small-molecule PDGFR/CSF1R/c-KIT kinase inhibitor in clinical developm …
Imatinib-induced generalized vitiligo.
Jain A. Jain A. Br J Haematol. 2022 Jun;197(5):511. doi: 10.1111/bjh.18096. Epub 2022 Mar 14. Br J Haematol. 2022. PMID: 35285938 No abstract available.
Transvaginal resection of gastrointestinal stromal tumor in the rectum.
Penninga L, Smith HG, Brinch CM, Krarup-Hansen A, Preisler L. Penninga L, et al. Ugeskr Laeger. 2023 Jun 19;185(25):V02230116. Ugeskr Laeger. 2023. PMID: 37381838 Free article. Danish.
The primary treatment of GIST is surgical resection. Neoadjuvant imatinib treatment may cause tumor reduction and allow local resection. This is a case report of a 70-year-old woman with a high level of comorbidity who was diagnosed with a low rectal GIST. She was successf …
The primary treatment of GIST is surgical resection. Neoadjuvant imatinib treatment may cause tumor reduction and allow local resecti …
Horizontal melanonychia.
Salman A, Eser A, Kaygusuz Atagunduz I, Ergun T. Salman A, et al. Actas Dermosifiliogr. 2017 Jun;108(5):469-470. doi: 10.1016/j.ad.2016.01.014. Epub 2016 Aug 16. Actas Dermosifiliogr. 2017. PMID: 27543192 Free article. English, Spanish. No abstract available.
Imatinib-induced eruptive nevi.
Hamie L, Sawaya RT, Abbas O. Hamie L, et al. Clin Exp Pharmacol Physiol. 2021 Sep;48(9):1298-1299. doi: 10.1111/1440-1681.13491. Epub 2021 Mar 25. Clin Exp Pharmacol Physiol. 2021. PMID: 33768564
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. ...Despite the well-known association of eruptive melanocytic nevi with the use of other tyrosine kinase inhibitors, this phenomenon has not been linked to …
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. ...Despite the …
Adjuvant imatinib for GIST: duration likely matters.
Eriksson M, Joensuu H. Eriksson M, et al. Ann Oncol. 2021 Apr;32(4):434-436. doi: 10.1016/j.annonc.2021.01.073. Epub 2021 Jan 29. Ann Oncol. 2021. PMID: 33524476 Free article. No abstract available.
18,281 results
You have reached the last available page of results. Please see the User Guide for more information.